Here is your Pro Recap of 5 head-turning deal dispatches you may have missed last week: Overstock.com acquires Bed Bath & Beyond brand, Visa buys Pismo for $1 billion, Bausch + Lomb acquires a range of eye-care products from Novartis, and merger deals at Eli Lilly and Sigilon Therapeutics, and 3D Systems and Desktop Metal.

Hot M&A headlines like these are posted in real time for InvestingPro subscribers. Never miss another market-moving headline.

Overstock picks Bed Bath & Beyond brand and other intellectual property

Overstock.com (NASDAQ:OSTK) announced on Wednesday that it had bought intellectual property from the beleaguered Bed Bath & Beyond (OTC:BBBYQ) through a bankruptcy court process, including website, trademarks, patents, customer database, loyalty program data, and other brand assets. The transaction excludes physical store-related assets. The $21.5 million cash acquisition was approved by the U.S. Bankruptcy Court.

Within the next week, Overstock plans to relaunch the Bed Bath & Beyond domain in Canada, followed weeks later by the relaunch of a refreshed website, mobile app, and loyalty program in the United States.

Overstock.com shares gained more than 36% last week.

Visa buys Pismo for $1 billion

Visa (NYSE:V) announced on Wednesday it agreed to acquire Pismo, a cloud-native issuer processing and core banking platform operating in Latin America, Asia Pacific, and Europe, for $1 billion in cash.

This acquisition will enable Visa to offer core banking and issuer processing capabilities for debit, prepaid, credit, and commercial cards through cloud-native APIs.

Bausch + Lomb surges following its acquisition of Novartis drugs for $1.75B

Bausch + Lomb (NYSE:BLCO) announced that it would purchase a range of eye-care products from Novartis (NYSE:NVS) for $1.75B. This news led to a surge of more than 4% in Bausch + Lomb shares on Friday.

The deal includes the acquisition of Xiidra, an anti-inflammation eye drop, the experimental drug libvatrep for chronic ocular surface pain, and the rights to use Novartis' AcuStream dry-eye drug delivery device.

The agreement is expected to be completed by year-end.

Eli Lilly buys Sigilon Therapeutics

Eli Lilly (NYSE:LLY) will acquire Sigilon Therapeutics (NASDAQ:SGTX), a biopharmaceutical company focused on developing functional cures for various acute and chronic diseases. Sigilon Therapeutics shares jumped more than 438% on Thursday.

Lilly will initiate a tender offer to purchase all outstanding shares of Sigilon at $14.92 per share in cash ($34.6M in total). Additionally, each share will include a non-tradeable contingent value right (CVR), providing the opportunity to receive up to an extra $111.64 per share in cash. The potential total consideration per share is $126.56 in cash, excluding shares owned by Lilly (up to approximately $309.6M).